Clinical Trials · NCT05341089
A Study of Two Different Formulations of LY3502970 in Healthy Participants
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 39
- Start date
- May 2022
- Locations
- 1 site, Singapore
- Primary endpoint
- Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970 in Formulation 1 and Formulation 2